Kezar Life Sciences (KZR)
(Real Time Quote from BATS)
$0.63 USD
+0.01 (0.87%)
Updated Aug 16, 2024 11:52 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Kezar Life Sciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 7 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 118 | 71 | 55 | 43 | 37 |
Income After Depreciation & Amortization | -111 | -71 | -55 | -43 | -37 |
Non-Operating Income | 11 | 4 | 0 | 1 | 2 |
Interest Expense | 2 | 1 | 0 | 0 | 0 |
Pretax Income | -102 | -68 | -55 | -42 | -35 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -102 | -68 | -55 | -42 | -35 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -102 | -68 | -55 | -42 | -35 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -117 | -71 | -51 | -41 | -37 |
Depreciation & Amortization (Cash Flow) | -6 | 0 | 3 | 2 | 0 |
Income After Depreciation & Amortization | -111 | -71 | -55 | -43 | -37 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 72.55 | 67.37 | 52.76 | 44.00 | 19.08 |
Diluted EPS Before Non-Recurring Items | -1.31 | -1.01 | -1.04 | -0.95 | -1.84 |
Diluted Net EPS (GAAP) | -1.40 | -1.01 | -1.04 | -0.95 | -1.84 |
Fiscal Year end for Kezar Life Sciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 7.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 7.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 23.71 | 28.40 | 32.53 | 26.79 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -23.71 | -28.40 | -25.53 | -26.79 |
Non-Operating Income | NA | 2.45 | 2.73 | 2.82 | 2.86 |
Interest Expense | NA | 0.40 | 0.40 | 0.40 | 0.39 |
Pretax Income | NA | -21.66 | -32.26 | -23.10 | -24.31 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -21.66 | -32.26 | -23.10 | -24.31 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -21.66 | -32.26 | -23.10 | -24.31 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 72.80 | 72.74 | 72.68 | 72.46 |
Diluted EPS Before Non-Recurring Items | NA | -0.30 | -0.35 | -0.32 | -0.34 |
Diluted Net EPS (GAAP) | NA | -0.30 | -0.43 | -0.32 | -0.34 |